← Back to patent-cliff list
CAS 3886-69-9
(R)-1-phenylethan-1-amine(R)-(-)-1-Phenylethylamine
Codes: ATOR-012, Tamsulosin Hydrochloride-002, ROSU-039, FINA-034, SITAF-010, MITI-013, R-fluoxetine-003
Application context (from source-drug indications)
Type 2 diabetesAtorvastatin Calcium Hydrate/Metformin HydrochlorideHyperlipidaemiaAtorvastatin Calcium Hydrate/Metformin HydrochlorideErectile dysfunctionTadalafil/TamsulosinBenign prostatic hyperplasiaTadalafil/TamsulosinHypertensionFimasartan potassium trihydrate/Rosuvastatin calciumDyslipidaemiaFimasartan potassium trihydrate/Rosuvastatin calciumHypertensionRosuvastatin Calcium/TelmisartanHyperlipidaemiaRosuvastatin Calcium/TelmisartanOtitis externaFinafloxacinOtitis media with effusionFinafloxacinOtitis mediaFinafloxacinUrinary tract infectionFinafloxacinPyelonephritisFinafloxacinGram-negative bacterial infectionFinafloxacinHypertensionAtorvastatin Calcium Hydrate/IrbesartanHyperlipidaemiaAtorvastatin Calcium Hydrate/IrbesartanLower urinary tract symptomsSolifenacin Succinate/Tamsulosin HydrochlorideBenign prostatic hyperplasiaSolifenacin Succinate/Tamsulosin HydrochlorideOveractive bladderSolifenacin Succinate/Tamsulosin HydrochlorideDrug-related adverse effects and reactionsSolifenacin Succinate/Tamsulosin HydrochlorideBladder neck obstructionSolifenacin Succinate/Tamsulosin HydrochlorideBenign prostatic hyperplasiaDutasteride/Tamsulosin HydrochlorideHypercholesterolaemiaAtorvastatin Calcium Hydrate/RamiprilHypertensionAtorvastatin Calcium Hydrate/RamiprilCystitisSitafloxacin HydrateSinusitisSitafloxacin HydrateTonsillitisSitafloxacin HydratePneumoniaSitafloxacin HydrateCervicitisSitafloxacin HydratePericoronitisSitafloxacin HydrateHyperlipoproteinaemia type IIIAtorvastatin Calcium HydrateHyperlipidaemiaAtorvastatin Calcium HydrateHeterozygous familial hypercholesterolaemiaAtorvastatin Calcium HydrateHeart failureAtorvastatin Calcium HydrateType 2 diabetesAtorvastatin Calcium HydrateStrokeAtorvastatin Calcium HydrateBenign prostatic hyperplasiaTamsulosin HydrochlorideUrinary tract infectionTamsulosin HydrochlorideUrinary retentionTamsulosin HydrochlorideInguinal herniaTamsulosin HydrochlorideVoiding dysfunctionTamsulosin HydrochlorideLower urinary tract symptomsTamsulosin HydrochlorideHomozygous familial hypercholesterolaemiaRosuvastatin CalciumHeterozygous familial hypercholesterolaemiaRosuvastatin CalciumHyperlipoproteinaemia type IIIRosuvastatin CalciumAtherosclerosisRosuvastatin CalciumHyperlipoproteinaemia type IIRosuvastatin CalciumHypercholesterolaemiaRosuvastatin CalciumType 2 diabetesMitiglinideDiabetesMitiglinide分离性焦虑R-fluoxetineAnxietyR-fluoxetineAnxiety disorderR-fluoxetine
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Atorvastatin Calcium Hydrate/Metformin Hydrochloride | Tier C — Watch / trade | - |
| Tadalafil/Tamsulosin | Tier C — Watch / trade | - |
| Fimasartan potassium trihydrate/Rosuvastatin calcium | Tier C — Watch / trade | - |
| Rosuvastatin Calcium/Telmisartan | Tier C — Watch / trade | - |
| Finafloxacin | Tier C — Watch / trade | - |
| Atorvastatin Calcium Hydrate/Irbesartan | Tier C — Watch / trade | - |
| Solifenacin Succinate/Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| Dutasteride/Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| Atorvastatin Calcium Hydrate/Ramipril | Tier C — Watch / trade | - |
| Sitafloxacin Hydrate | Tier C — Watch / trade | - |
| Atorvastatin Calcium Hydrate | Tier B — Position early | - |
| Tamsulosin Hydrochloride | Tier C — Watch / trade | - |
| Rosuvastatin Calcium | Tier B — Position early | - |
| Mitiglinide | Tier C — Watch / trade | - |
| R-fluoxetine | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
ethyl 2-bromo-2-(4-fluorophenyl)acetate→2-(1,3-dioxolan-2-yl)ethanamine→ethyl 2-((2-(1,3-dioxolan-2-yl)ethyl)amino)-2-(4-fluorophenyl)acetate→isobutyryl chloride→2-(N-(2-(1,3-dioxolan-2-yl)ethyl)isobutyramido)-2-(4-fluorophenyl)acetic acid→N,3-diphenylpropiolamide→1-(2-(1,3-dioxolan-2-yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide→5-(4-fluorophenyl)-2-isopropyl-1-(3-oxopropyl)-N,4-diphenyl-1H-pyrrole-3-carboxamide→methyl 7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-5-hydroxy-3-oxoheptanoate→(3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid→5-(4-fluorophenyl)-1-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide→(R)-1-phenylethan-1-amine→1-((3R,5R)-3,5-dihydroxy-7-oxo-7-(((R)-1-phenylethyl)amino)heptyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide→5-(4-fluorophenyl)-1-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide→sodium (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate
1-(4-Methoxyphenyl)-2-propanone→(R)-(-)-1-Phenylethylamine→(2R)-1-(4-Methoxyphenyl)-N-[(1R)-1-phenylethyl]propan-2-amine hydrochloride→2-Methoxy-5-[(2R)-2-[[(1R)-1-phenylethyl]amino]propyl]benzenesulfonamide→5-[(2R)-2-Aminopropyl]-2-methoxybenzenesulfonamide hydrochloride→2-Methoxy-5-[(2R)-2-[[(1R)-1-phenylethyl]amino]propyl]benzenesulfonamide hydrochloride→(2-Ethoxyphenoxy)acetaldehyde→(-)-5-[2(R)-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide→1-(2-Bromoethoxy)-2-ethoxybenzene→1-Hydroxy-2-ethoxybenzene→1,3-Dioxolan-2-one→2-(2-Ethoxyphenoxy)ethanol
1-(4-Methoxyphenyl)-2-propanone→(R)-(-)-1-Phenylethylamine→1-(4-Methoxyphenyl)-N-[1(R)-phenylethyl]propan-2(R)-amine→5-[(2R)-2-aminopropyl]-2-methoxybenzene-1-sulfonic acid→1-(2-Bromoethoxy)-2-ethoxybenzene→5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzene-1-sulfonic acid→5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonyl chloride
2-Methoxy-5-(2-oxopropyl)benzene-1-sulfonamide→(R)-(-)-1-Phenylethylamine→2-Methoxy-5-[(2R)-2-[[(1R)-1-phenylethyl]amino]propyl]benzenesulfonamide hydrochloride→5-(2(R)-Aminopropyl)-2-methoxybenzenesulfonamide→5-[(2R)-2-Aminopropyl]-2-methoxybenzenesulfonamide hydrochloride→1-(2-Bromoethoxy)-2-ethoxybenzene→(-)-5-[2(R)-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide→2-(2-Ethoxyphenoxy)ethyl mesylate
1-(4-Methoxyphenyl)-2-propanone→(R)-(-)-1-Phenylethylamine→(2E)-1-(4-Methoxyphenyl)-N-[(1R)-1-phenylethyl]propan-2-imine→1-(4-Methoxyphenyl)-N-[1(R)-phenylethyl]propan-2(R)-amine→(-)-2-(4-Methoxyphenyl)-1-methylethanamine→(+/-)-tert-Butyl sulfinamide→(SR)-N-[(2E)-1-(4-Methoxyphenyl)propan-2-ylidene]-2-methylpropane-2-sulfinamide→(SR)-N-[(2R)-1-(4-Methoxyphenyl)propan-2-yl]-2-methylpropane-2-sulfinamide
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | Carbamic acid, (7S)-5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI) Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.